RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
        • 주제분류
        • 발행연도
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • SCISCIESCOPUS

        Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study

        Oh, Jaeseong,Lee, SeungHwan,Kim, Anhye,Yoon, Jangsoo,Jang, Kyungho,Lee, Doo H.,Cho, Sunyoung,Lee, Sang Rim,Yu, Kyung-Sang,Chung, Jae-Yong Hall Associates, etc 2018 The Journal of Clinical Pharmacology Vol.58 No.1

        <P>VVZ-149, a dual antagonist of GlyT2 and 5HT(2)A receptors, is an investigational analgesic with a novel mechanism of action that is currently under early-stage clinical development as an injectable agent for the treatment of postoperative pain. Here, the safety, tolerability, and pharmacokinetics of VVZ-149 injections in healthy male volunteers were explored in a randomized, double-blind, single- and multiple-ascending-dose (SAD and MAD, respectively), placebo-controlled clinical study. Subjects randomly received a 4-hour intravenous infusion of 0.25-8 mg/kg VVZ-149 or placebo in the SAD study (n = 46) or a 4-hour intravenous infusion of 4-7 mg/kg VVZ-149 or placebo twice daily for 3 days in the MAD study (n = 20). Serial blood and urine samples were collected for the pharmacokinetic analysis of VVZ-149 and its active metabolite (VVZ-368). Noncompartmental and compartmental pharmacokinetic analyses were performed. Various dosing scenarios were simulated to identify the adequate dosing regimen for the subsequent trials. Plasma exposure to VVZ-149 and VVZ-368 showed a dose-proportional increase. VVZ-149 did not accumulate in the plasma, whereas the plasma concentration of VVZ-368 increased by 1.23- to 2.49-fold after the fifth and sixth doses, respectively, in the MAD trial. Among the simulated dosing regimens, a loading dose followed by a maintenance dose was found to be an optimal dosing regimen, yielding the effective concentration estimated from animal studies in rat models of neuropathic or inflammatory pain. Single- or multiple-dose administration of VVZ-149 was generally well tolerated. These results showed that 0.5-8 mg/kg VVZ-149 exhibited linear pharmacokinetic characteristics and can be safely administered in further clinical studies.</P>

      • KCI등재

        GE 7FA+e DLN-2.6 가스터빈 연소기 연구

        오정석(Jeongseog Oh),김민기(Minki Kim),허필원(Pilwon Heo),이장수(Jangsoo Lee),윤영빈(Youngbin Yoon) 한국추진공학회 2008 한국추진공학회지 Vol.12 No.5

        Combustion vibration and yellow plume are frequently occurred during an initial operating mode in GE 7FA+e DLN-2.6 combustors which are running at Seo-Inchon combined cycle power plant. The objectives of this paper are to analyze the causes of those two phenomena and to study non-dimensional factors to design a lab scale dump combustor. With the consideration of real combustor, the peak frequencies of vibration is 120~140 Hz due to cold flow in plenum. This plenum is considered as a major parameter in the lab scale dump combustor design. In addition, other important design factors are the nozzle swirl number, the mixing distance, the expansion ratio of dump and nozzle area, and the acoustic impedance at a nozzle and a exhaust plug etc.

      • SCISCIESCOPUS

        Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers

        Park, Sang-In,Oh, Jaeseong,Jang, Kyungho,Yoon, Jangsoo,Moon, Seol Ju,Park, Jong Sun,Lee, Jae Ho,Song, Junghan,Jang, In-Jin,Yu, Kyung-Sang,Chung, Jae-Yong American Society for Microbiology 2015 Antimicrobial Agents and Chemotherapy Vol.59 No.8

        <P>Therapeutic drug monitoring (TDM) of second-line antituberculosis drugs would allow for optimal individualized dosage adjustments and improve drug safety and therapeutic outcomes. To evaluate the pharmacokinetic (PK) characteristics of clinically relevant, multidrug treatment regimens and to improve the feasibility of TDM, we conducted an open-label, multiple-dosing study with 16 healthy subjects who were divided into two groups. Cycloserine (250 mg), <I>p</I>-aminosalicylic acid (PAS) (5.28 g), and prothionamide (250 mg) twice daily and pyrazinamide (1,500 mg) once daily were administered to both groups. Additionally, levofloxacin (750 mg) and streptomycin (1 g) once daily were administered to group 1 and moxifloxacin (400 mg) and kanamycin (1 g) once daily were administered to group 2. Blood samples for PK analysis were collected up to 24 h following the 5 days of drug administration. The PK parameters, including the maximum plasma concentration (<I>C</I><SUB>max</SUB>) and the area under the plasma concentration-time curve during a dosing interval at steady state (AUC<SUB>τ</SUB>), were evaluated. The correlations between the PK parameters and the concentrations at each time point were analyzed. The mean <I>C</I><SUB>max</SUB> and AUC<SUB>τ</SUB>, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter. The results indicated that sampling at 1, 2.5, and 6 h postdosing is needed for TDM when all seven drugs are administered concomitantly. This study indicates that PK characteristics must be considered when prescribing optimal treatments for patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT02128308.)</P>

      • Comparative Study of Dry Storage Condition Characteristics of HANA and Commercial Cladding

        Yongsik Yang,Jaeyong Kim,Jongdae Hong,Jangsoo Oh,Juyeop Park 한국방사성폐기물학회 2023 한국방사성폐기물학회 학술논문요약집 Vol.21 No.2

        In nuclear fuel development research, consideration of the back-end cycle is essential. In particular, a review of an in-reactor performance of nuclear fuel related to the various degradation phenomena that can occur during spent fuel dry storage is an important area. The important factors affecting the degradation of zirconium-based cladding during dry storage are the cladding’s hydrogen concentration and rod internal pressure after irradiation. In this study, a preliminary analysis of the in-reactor behavior of the HANA cladding, which has been developed and is currently undergoing licensing review, was performed, and based on this result, a comparative analysis between nuclear fuel with HANA cladding and current commercial fuel under storage conditions was performed. The results show that the rod internal pressure of nuclear fuel with HANA cladding is not significantly different from that of commercial cladding, and the hydrogen concentration in the cladding tends to reduce due to the increased corrosion resistance, so fuel integrity in a dry storage conditions is not expected to be a major problem. Although the lack of cladding creep data under dry storage conditions, the results from the Halden research reactor test comparing in-reactor creep behavior with Zircaloy-4 showed that there is sufficient margin for degradation due to creep during storage.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼